Mehra Uneek
SEC insider (Form 3/4/5 filer). CIK 0001881504. Chief Financial Officer at BridgeBio Oncology Therapeutics, Inc. (BBOT) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Apr 1, 2026. Located in SOUTH SAN FRANCISCO, CA.
Companies Mehra Uneek has filed insider reports for
- BridgeBio Oncology Therapeutics, Inc. (BBOT): Officer, Chief Financial Officer
- 4D Molecular Therapeutics, Inc. (FDMT): Officer, See Remarks
Mehra Uneek
CIK: 0001881504
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Apr 1, 2026BBOT
BridgeBio Oncology Therapeutics, Inc.
Tax PaymentDirect524 shares at avg. $9.03$5K - Mar 10, 2026BBOT
BridgeBio Oncology Therapeutics, Inc.
AwardDirect23.3K shares- - Aug 26, 2025BBOT
BridgeBio Oncology Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
633.6K shares- - Mar 6, 2025FDMT
4D Molecular Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
130K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Apr 1, 2026 |  BBOT BridgeBio Oncology Therapeutics, Inc. | Tax Payment | 524 | $9.03 | $4,732 | Direct |
| Mar 10, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | Award | 23,330 | - | $0 | Direct |
| Aug 26, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | Award Stock Option (Right to Buy) | 633,570 | - | - | Direct |
| Mar 6, 2025 |  FDMT 4D Molecular Therapeutics, Inc. | Award Stock Option (Right to Buy) | 130,000 | - | - | Direct |
1-4 of 4 transactions